Recent advances in head and neck cancer.
Haddad
Robert I
RI
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. robert_haddad@dfci.harvard.edu
Shin
Dong M
DM
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D000068818:Cetuximab; D003131:Combined Modality Therapy; D018450:Disease Progression; D066246:ErbB Receptors / Q000502:physiology; D042822:Genomic Instability; D006258:Head and Neck Neoplasms / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D052162:Human papillomavirus 16; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications; D011878:Radiotherapy; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D000068818:Cetuximab